What stage is this research?
This research is in the preclinical phase, meaning it has not advanced to clinical trials involving people yet.
This research is in the preclinical phase, meaning it has not advanced to clinical trials involving people yet.
Wave Life Sciences is conducting discovery research in Cambridge, MA, and in collaboration with Dr. Matthew Wood at the University of Oxford in the UK. This research is being funded by Wave Life Sciences.
The goal of this early research is to work toward developing a medicine for people with Duchenne muscular dystrophy amenable to exon 53 skipping.
Required research studies must be completed and regulatory applications filed and approved prior to initiating a clinical trial.
The company expects to run a global clinical trial and hopes to have clinical trial sites in the United States. Sites have not been selected at this time.
Please visit www.wavelifesciences.com or email medicalinformation@wavelifesci.com for additional information.